MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Onconova Therapeutics Retained Earnings 2011-2026 | ONTX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Onconova Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -649 M | -483 M | -464 M | -445 M | - | -403 M | -382 M | -362 M | -338 M | -319 M | -295 M | -231 M | -168 M | -138 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -138 M | -649 M | -360 M |
Quarterly Retained Earnings Onconova Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -633 M | -629 M | -628 M | -649 M | -619 M | - | -488 M | -483 M | -478 M | -474 M | -469 M | -464 M | -458 M | -453 M | -449 M | -445 M | -441 M | -438 M | -433 M | -429 M | -429 M | -429 M | -429 M | -403 M | -403 M | -403 M | -403 M | -382 M | -382 M | -382 M | -382 M | -362 M | -362 M | -362 M | -362 M | -338 M | -338 M | -338 M | -338 M | -319 M | -319 M | -319 M | -319 M | -295 M | -295 M | -295 M | -295 M | -231 M | -231 M | -231 M | -231 M | -168 M | -168 M | -168 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -168 M | -649 M | -390 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
-133 M | $ 2.75 | 1.1 % | $ 229 M |  Schweiz |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
argenx SE
ARGX
|
-861 M | $ 838.44 | -0.22 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 234.35 | -0.07 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.82 | 1.69 % | $ 4.47 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.44 | 3.42 % | $ 8.28 B |  Australia |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Atea Pharmaceuticals
AVIR
|
-364 M | $ 4.59 | -1.29 % | $ 387 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 166.74 | -1.89 % | $ 8.29 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.24 | -0.8 % | $ 1.83 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
20.6 B | $ 193.59 | -0.79 % | $ 28.4 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
-195 M | $ 62.08 | -0.86 % | $ 11.8 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 111.75 | 0.66 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
-607 M | $ 14.73 | 0.44 % | $ 4.55 B | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |